HUE048750T2 - (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére - Google Patents
(R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezeléséreInfo
- Publication number
- HUE048750T2 HUE048750T2 HUE15702312A HUE15702312A HUE048750T2 HU E048750 T2 HUE048750 T2 HU E048750T2 HU E15702312 A HUE15702312 A HU E15702312A HU E15702312 A HUE15702312 A HU E15702312A HU E048750 T2 HUE048750 T2 HU E048750T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolodin
- methylbenzyl
- piperidin
- prodrugs
- hydroxyphenyl
- Prior art date
Links
- -1 (3S, 4S) -3-fluoro-4- (4-hydroxyphenyl) piperidin-1-yl Chemical group 0.000 title 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE048750T2 true HUE048750T2 (hu) | 2020-08-28 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15702312A HUE048750T2 (hu) | 2014-01-09 | 2015-01-08 | (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (enExample) |
| EP (2) | EP3677578A1 (enExample) |
| JP (1) | JP6629738B2 (enExample) |
| KR (1) | KR102331120B1 (enExample) |
| AR (1) | AR102019A1 (enExample) |
| AU (1) | AU2015204785A1 (enExample) |
| CA (1) | CA2936338A1 (enExample) |
| CL (1) | CL2016001744A1 (enExample) |
| CY (1) | CY1122768T1 (enExample) |
| DK (1) | DK3092223T3 (enExample) |
| EA (1) | EA201691133A1 (enExample) |
| ES (1) | ES2771825T3 (enExample) |
| HR (1) | HRP20200161T1 (enExample) |
| HU (1) | HUE048750T2 (enExample) |
| IL (1) | IL246596A0 (enExample) |
| LT (1) | LT3092223T (enExample) |
| MX (1) | MX2016008715A (enExample) |
| PE (1) | PE20160898A1 (enExample) |
| PL (1) | PL3092223T3 (enExample) |
| PT (1) | PT3092223T (enExample) |
| RS (1) | RS59858B1 (enExample) |
| SG (1) | SG11201605620QA (enExample) |
| SI (1) | SI3092223T1 (enExample) |
| SM (1) | SMT202000094T1 (enExample) |
| TW (1) | TW201612169A (enExample) |
| UY (1) | UY35946A (enExample) |
| WO (1) | WO2015105929A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| ES2818254T3 (es) * | 2015-10-14 | 2021-04-09 | Bristol Myers Squibb Co | Antagonistas selectivos de NR2B |
| JP6843853B2 (ja) * | 2015-10-14 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 選択的ｎｒ２ｂアンタゴニスト |
| US12086719B2 (en) * | 2019-10-11 | 2024-09-10 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| ATE337292T1 (de) | 2000-04-26 | 2006-09-15 | Warner Lambert Co | Trans-n- 4-(4-hydroxyphenyl)cyclohexylö-3- phenylpropionamid als subtyp-selektiver nmda rezeptor antagonist |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| DK1648882T3 (da) | 2003-06-04 | 2008-11-24 | Merck & Co Inc | 3-fluor-piperidiner som NMDA/NR2B-antagonister |
| CA2541162A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Inc. | Fused lactam compounds |
| EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
| CN103058957A (zh) | 2007-06-29 | 2013-04-24 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| JP2011503112A (ja) * | 2007-11-13 | 2011-01-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物 |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko not_active Expired - Fee Related
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 SM SM20200094T patent/SMT202000094T1/it unknown
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja not_active Expired - Fee Related
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en not_active Ceased
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400030I1 (hu) | Aril, heteroaril és heterociklusos vegyületek komplement által közvetített rendellenességek kezelésére | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| HUE050155T2 (hu) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére | |
| LT3545079T (lt) | Kontroliuojama transkripcija | |
| JP2016028092A5 (enExample) | ||
| LT3224269T (lt) | Kompozicijos ir būdai, skirti cns sutrikimams gydyti | |
| LT3261640T (lt) | 5ht agonistai epilepsijos sutrikimų gydymui | |
| LT3250210T (lt) | Kompozicijos ir būdai, skirti gydyti cns sutrikimus | |
| JP2016065085A5 (enExample) | ||
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| MX2017001416A (es) | Sales co-formadoras de (2s,3s)-7-fluoro-2-(4-fluorofenil)-3-(1-met il-1h-1,2,4-triazol-5-il)-4-oxo-1,2,3,4-tetrahidroquinolin-5-carb oxilato de metilo y sus metodos de preparacion. | |
| LT3416957T (lt) | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui | |
| IL283948A (en) | Methods for treating depression | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| HUE048750T2 (hu) | (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| HUE046116T2 (hu) | Biotin, demielinizációs neuropátiák kezelésére | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| HUE053358T2 (hu) | 5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére | |
| LT3448382T (lt) | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti | |
| EP3532044A4 (en) | HDAC INHIBITOR COMPOSITIONS FOR CHROMOSOME X REACTIVATION |